As AstraZeneca's Crestor goes off patent, generic cos to jump in

Cardiac drug Crestor or Generic Rosuvastatin, an AstraZeneca invention, will be going off patent in the US tomorrow, reported Ekta Batra of CNBC-TV18.  It is said to be one of the biggest launches for USFDA this year and the market size for the drug is pegged at about USD 3 billion. So far, 11 companies have filed for the generic version of this drug and have tentative approval, too. At least, 5-7 companies including Glenmark Pharmaceuticals and Alkem Laboratories have supplies ready to launch tomorrow itself. The generic companies with a final approval can make USD 15 million to over USD 20 million from the launch.  Watch video for more details